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Novel Hyaluronic Acid-Chitosan Nanoparticles for
Ocular Gene Therapy
Maria de la Fuente, Begoña Seijo, and Maria J. Alonso
PURPOSE. Gene therapy offers a promising alternative for the
treatment of ocular diseases. However, the implementation of
this type of therapy is actually hampered by the lack of an
efficient ocular gene delivery carrier. The main objective of the
present work was to assess the effectiveness and investigate
the mechanism of action of a new type of nanoparticle made of
two bioadhesive polysaccharides, hyaluronic acid (HA) and
chitosan (CS), intended for the delivery of genes to the cornea
and conjunctiva.
METHODS. The nanoparticles were obtained by a very mild
ionotropic gelation technique. They were loaded with either
the model plasmid pEGFP or p-gal. Transfection and toxico-
logical studies were conducted in human corneal epithelial
(HCE) and normal human conjunctival (IOBA-NHC) cell lines.
The mechanism of internalization of the nanoparticles by the
corneal and conjunctival cells was investigated by using fluo-
rescence confocal microscopy.
RESULTS. The nanoparticles had a size in the range of 100 to 235
nm and a -potential of 30 to 28 mV. The results of the
transfection studies showed that HA-CS nanoparticles were
able to provide high transfection levels (up to 15% of cells
transfected), without affecting cell viability. The confocal im-
ages indicated that HA-CS nanoparticles were internalized by
fluid endocytosis and that this endocytic process was mediated
by the hyaluronan receptor CD44.
CONCLUSIONS. The results give evidence of the potential of
HA-CS nanoparticles for the targeting and further transfer of
genes to the ocular surface. (Invest Ophthalmol Vis Sci. 2008;
49:2016–2024) DOI:10.1167/iovs.07-1077
Gene delivery holds special promise for the treatment ofocular diseases.1 As with any other modality of adminis-
tration, a major challenge in ocular gene therapy has become
the effective delivery of genetic material to the nucleus of the
target cell.2,3 In recent years, nonviral vectors and especially
those resulting from the use of nanotechnologies have received
increasing attention for achieving the delivery of genetic ma-
terial to the eye.4–7 The selection of the route of administration
depends primarily on the target tissue, being traditionally the
topical and the subconjunctival used for anterior targets.8
However, presumably due to tear flow, blinking and low pen-
etration of the vector through epithelial tight junctions, the
challenge of achieving effective topical gene transfer has led to
the prevalence of invasive administration to the anterior cham-
ber and corneal stroma.9 As a consequence, for the instillation
of genes over the ocular surface, the development of a suitable
delivery system becomes a requisite for achieving effective
concentrations at the intended site over a sufficient period
after administration. One of the most promising current ap-
proaches relies on the use of mucoadhesive nanoparticles that
interact with the ocular mucosa, thus increasing the contact
time on the eye surface.10,11
With this premise in mind, we developed nanoparticles
consisting of two bioadhesive and biocompatible polysaccha-
rides, hyaluronic acid (HA) and chitosan (CS), intended for the
delivery of complex macromolecules to the ocular surface.
The original idea of incorporating HA into the nanoparticles
was conceived to improve their cellular targeting capacity.
Indeed, apart from its biocompatibility, biodegradability, and
mucoadhesive character, HA is known for its implication in
several processes, such as the regeneration of corneal and
conjunctival epithelial cells, through an interaction with the
CD44 receptor.12 CD44 is expressed in the human cornea and
conjunctiva13,14 and participates in a wide variety of cellular
functions, including receptor-mediated internalization and deg-
radation of hyaluronan.15,16 For example, this receptor-medi-
ated process has been reported to be the mechanistic expla-
nation for the cellular uptake of HA-targeted liposomes to
tumor cells that overexpress the CD44 receptor.17
On the other hand, our group has found that both CS
nanoparticles and liposome-CS nanoparticle complexes inter-
act with and penetrate the corneal and conjunctival epithe-
lia.18–20 Moreover, CS is a biocompatible polysaccharide that
has been extensively used for cell transfection.21–23
Hence, our goal in the present work was to evaluate the
potential of a new gene nanocarrier, consisting of HA and CS,
specially designed for the specific targeting and intracellular
delivery of genes into the ocular epithelial cells. With this idea
in mind, we prepared different nanoparticulate compositions,
with regard for the polysaccharides molecular weight and
HA-CS mass ratios, and studied their cytotoxicity, transfection
efficiency, and cell uptake in two cell models: human corneal
epithelial (HCE) and normal human conjunctival (IOBA-NHC)
cells. Finally, the capacity of the nanoparticles to interact with
the CD44 receptor was explored, as well as the role of this
interaction in gene transfer.
MATERIALS AND METHODS
Chemicals
Sodium hyaluronate ophthalmic grade (having a molecular mass of
170 kDa) was a gift from Bioibérica (Barcelona, Spain). Ultrapure
chitosan hydrochloride salt (Protasan UP CL 113, having a molecular
mass of 110 kDa) was purchased from Pronova Biomedical A.S.
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(Oslo, Norway). Plasmid DNA (pDNA) encoding green fluorescent
protein (pEGFP-C1) and pDNA encoding -galactosidase (p-gal)
driven by a CMV promoter, were purchased from Elim Biopharmaceu-
ticals (Hayward, CA). Pentasodium tripolyphosphate (TPP), acetalde-
hyde, ONPG (2-Nitrophenyl -D-galactopyranoside), and -galactosi-
dase, were all obtained from Sigma-Aldrich (Madrid, Spain).
Fluoresceinamine and cyclohexyl isocyanide were purchased from
Fluka (Madrid, Spain). A 1-kbp DNA ladder was obtained from Invitro-
gen-Life Technologies (Barcelona, Spain). All other solvents and chem-
icals were of the highest commercial grade available.
Depolymerization of CS and HA
Chitosan oligomers (CSO) were obtained from Protasan UP CL 113
(Novamatrix, Sandvika, Norway) by sodium nitrite degradation, as
previously described by Janes and Alonso.24 Briefly, 200 L of 0.1 M
NaNO2 was added to 4 mL of a CS solution of 10 mg/mL. The reaction
was left overnight, to ensure completion of the degradation, and
oligomers with 10- to 12-kDa molecular mass were recovered by
freeze-drying. The molecular size of the CSO was verified by size-
exclusion chromatography-multiangle laser-light scattering (SEC-
MALLS). An isocratic pump (G1310A Iso Pump; Hewlett Packard, Palo
Alto, CA) was connected to analytic PSS GPC columns (10 m, 30 Å,
8  50 mm, NOA0830103E1; and 10 m, 3000 Å, 8  300 mm,
NOA0830103E3; Novema, Wroclaw Poland). An SEC-MALLS system
(PSS SLD7000 MALLS detector; Brookhaven Instruments Corp., Holts-
ville, NY) operating at 660 nm and a refractive index detector (model
G1362A; Agilent, Palo Alto, CA) were connected online. A buffer
containing 0.15 M NH4OAc and 0.2 M AcOH (pH 4.5) was used as the
eluent. Polymer solutions were filtered through 0.2-m pore size
membranes (VWR International, Ltd., Lutterworth, UK) before injec-
tion. Polymer concentration was in the range of 0.30 to 0.16 mg/mL.
The refractive index increment dn/dC was set at 0.188.
For the enzymatic degradation of HA, 52.7 mg HA was dissolved in
20 mL of buffer (0.1 M sodium acetate, 0.1 M sodium chloride, pH 7.2)
under magnetic stirring. After HA was completely dissolved, 5 mg
hyaluronidase (from bovine testes, activity 1000 units/mg, Sigma-Al-
drich, St. Louis, MO) was added to the solution, which was then kept
for 24 hours in a shaking incubator at 37°C. After the enzymatic
splitting reaction the mixture was centrifuged (3500 g, 30 minutes) in
filters (Amicon Ultra, MWCO 10 kDa; Millipore Corp., Billerica, MA),
and the filtrated HA oligomers (HAO) of interest (MW 10 kDa) were
recovered by freeze drying.
Nanoparticle Preparation
Nanoparticles (NPs) were spontaneously obtained by ionotropic geli-
fication, according to the methodology previously developed by our
group albeit with minor modifications.25,26 The hyaluronan solution
(HA or HAO), mixed with the cross-linker TPP, was added over the
chitosan solution (CS or CSO) under magnetic stirring. Agitation was
maintained for 10 minutes, to allow the complete formation of the
system. The CS or CSO solution was prepared at a concentration of
0.625 mg/mL, and the volume used was fixed at 0.750 mL. Alterna-
tively 50 L of a TPP solution (0.5 mg/mL) were mixed with the HA or
HAO solution before the formation of the NPs. To modulate the weight
ratio of the polysaccharides that constituted the NPs (HA:CS 1:2, 1:1, or
2:1), we modulated the concentration and volumes of the hyaluronan
solution (0.625 or 1.25 mg/mL and 0.375 or 0.750 mL, respective-
ly).The NPs were loaded with pEGFP, or p-gal, by incorporating the
required amount of the model plasmid in the HA/TPP phase. The
theoretical loading was fixed at 7% (wt/wt).
NPs composed solely of CS were also prepared by ionic gelification.
In such a case, 0.2 mL of TPP at a concentration of 0.625 mg/mL were
added over 1 mL of CS (1 mg/mL). In the preparation of NPs made only
from CSO, 0.2 mL of TPP at a concentration or 0.42 mg/mL were added
over 1 mL of CSO solution (1 mg/mL). NPs were loaded by including
pEGFP in the TPP solution (7% wt/wt).
Nanoparticle Characterization
The mean particle size and the size distribution of the NPs were
determined by photon correlation spectroscopy (PCS). The -potential
values of the NPs were obtained by laser Doppler anemometry (LDA),
measuring the mean electrophoretic mobility. The PCS and LDA anal-
ysis were performed (Zetasizer 3000 HS; Malvern Instruments,
Malvern, UK).
The association of pDNA with the NP was observed by a conven-
tional agarose gel electrophoresis assay. Samples of the NPs were
placed in 1% agarose gel containing ethidium bromide and were run
for 90 minutes at 60 V (Sub-Cell GT 96/192; Bio-Rad Laboratories Ltd.,
Herts, UK) in TAE buffer (Tris-acetate-EDTA; pH 8).
Cell Cultures: HCE and IOBA-NHC Cells
Mycoplasma-free immortalized HCE cells were a gift from Arto Urtti
(University of Helsinki, Finland). HCE cells were cultured in DMEM:F12
(1:1) without L-glutamine, supplemented with 15% fetal bovine serum
and penicillin-streptomycin-L-glutamine (100 U/mL, 100 g/mL, and
0.3 mg/mL, respectively), and 5 g/mL insulin (Invitrogen-Gibco). EGF
(10 ng/mL; Invitrogen), 0.5% DMSO (Riedel de Haën, Seelze Germany),
and 0.1 g/mL cholera toxin (Gentaur, Brussels, Belgium) were also
added to the culture medium. The cells were maintained at 37°C with
a 5% CO2 humidified atmosphere. Cells of passages 38 to 40 were used
in the experiments.
Mycoplasma-free IOBA-NHC cells were a gift from IOBA (Instituto
de Oftalmobiologı́a Aplicada, University of Valladolid, Spain). IOBA-
NHC cells were grown in DMEM:F12 (1:1) without L-glutamine, sup-
plemented with 10% fetal bovine serum, penicillin-streptomycin-L-
glutamine (100 U/mL, 100 g/mL, and 0.3 mg/mL, respectively) and 1
g/mL insulin (Invitrogen-Gibco). EGF (2 ng/mL Invitrogen), 0.2
g/mL cholera toxin (Gentaur), 0.5 g/mL hydrocortisone, and am-
photericin B (Sigma-Aldrich) were added to the culture medium. The
cells were maintained at 37°C in a 5% CO2 humidified atmosphere.
Cells of passages 72 to 87 were used for the experiments.
Analysis of CD44 Expression by
Immunohistochemistry
HCE cells were seeded at a density of 3  105 cells in coverslips. After
24 hours’ incubation, the cells were washed with PBS and fixed with
2% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). They were
incubated with the blocking buffer (0.3% bovine serum albumin [BSA]
and 0.3% Triton-X in PBS) for 10 minutes to block nonspecific binding
and to permeabilize the cell walls. Hermes-1 antibody (obtained from
DSHB [Developmental Studies Hybridoma Bank], Iowa City, IA, and
developed by Eugene C. Butcher) was diluted 1:50 with 1% BSA in PBS
and incubated with the slides 2 hours at room temperature (RT). After
five washes with PBS, the cells were incubated for 1 hour at RT with
biotin-labeled anti-rat antibody (Anti-rat IgG; Sigma-Aldrich), diluted
1:100 in PBS. The cells were washed again with PBS and incubated
with avidin-peroxidase (16 L in 1000 L PBS; ExtrAvidin; Sigma-
Aldrich) for 30 minutes at RT. After washes with PBS, the cells were
incubated in DAB-peroxidase substrate (Sigma Fast; Sigma-Aldrich) for
3 minutes at RT. After they were washed with distilled water, the cells
were counterstained with Mayer’s hematoxylin (Sigma-Aldrich) for 5
minutes at RT, washed with water, and mounted in mounting medium
(Sigma-Aldrich). The specificity of the staining was controlled by incu-
bating sections without the primary antibody. The slides were exam-
ined with a light microscope equipped with a digital camera (Eclipse
TE 2000-S; Nikon Ltd., Kingston-upon-Thames, UK).
Measurement of Cytotoxicity of NPs
The cytotoxicity of the nanocarriers was studied in the HCE cells and
IOBA-NHC cells. The cells were seeded at a density of 3  104 cells per
well into 96-well culture plates (Costar, UK), 24 hours before the
experiment. Increasing doses of the pDNA-loaded NPs (5–160 g
NPs/cm2 cell culture) were incubated with the cells for 1 hour. After
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the NPs were removed, the cells were assayed for viability by using the
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymetoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium) colorimetric assay (Promega Corp., Madi-
son, WI).
Transfection Studies in Proliferating Cells
The capacity of the nanocarriers to transfect cells was evaluated in the
HCE and IOBA-NHC cells. Twenty-four hours before the experiment,
the cells were seeded at a density of 3  105 cells/well into 24-well
culture plates (Costar). Naked pDNA and pDNA-loaded NPs were
added to the cells in 300 L HBSS (1 g pDNA/well) and incubated for
5 hours. The cells were washed, and 1 mL of fresh culture medium was
added to each well. The medium was changed the day after the
transfection and every second day throughout the experiment. At
different time points after transfection, GFP-positive transfected cells
were detected by fluorescence microscopy (Eclipse TE 2000-S; Nikon
Ltd.). Image-analysis software (Photoshop Elements; Adobe, San Jose,
CA) was used to evaluate the GFP expression.
Cellular Uptake Studies
Sodium hyaluronate was labeled with fluoresceinamine (HA-fl), accord-
ing to a modification of the method described by de Belder and Wik.27
In brief, 20 mL DMSO was added to 40 mL of HA in water (1.25
mg/mL). Subsequently, 0.5 mL of fluoresceinamine (50 mg/mL in
DMSO), in the presence of 25 L cyclohexyl isocyanide and 25 L
acetaldehyde, were added to the HA solution. Magnetic stirring was
maintained for 5 hours in darkness. The HA-fl was precipitated with a
saturated solution of NaCl and ice-cold ethanol and then collected by
centrifugation. Precipitate HA-fl was dissolved in ultrapure water and
extensively dialyzed against distilled water for 24 hours, before lyoph-
ilization. The NPs were prepared according to the aforementioned
methodology.
HCE and IOBA-NHC cells were seeded at a density of 3  105 cells
per well, on sterile glass covers (Sigma-Aldrich) and placed in 24-well
culture plates (Costar). Twenty-four hours later, 50 L of the NP
suspension was incubated with the cells. After a 1-hour incubation,
cells were rinsed with PBS and fixed (3.5% paraformaldehyde/60 mM
saccharose in PBS) for observation with the confocal microscope. The
cell nuclei were counterstained with propidium iodide. Finally, the cell
fluorescence was analyzed with a confocal laser scanning microscope
(TCS SP2; Leica Microsystems, Wetzlar, Germany).
Study of the Interaction of the NPs with the
CD44 Receptor
To determine whether the cell uptake of the NPs was receptor medi-
ated, fluorescent NPs were added to the cells under different condi-
tions. (1) The NPs were incubated with the cells at 37°C for 1 hour.
Then, the cells were rinsed with PBS and fixed for observation with the
confocal microscope. The cell nuclei were counterstained with pro-
pidium iodide. (2) The NPs were incubated with the cells at 4°C for 1
hour. Then, the cells were washed three times in acidic PBS, and the
temperature was increased to 37°C for 20 minutes. Subsequently, the
cells were rinsed with PBS and fixed, and the cell nuclei were coun-
terstained. (3) The anti-human monoclonal antibody Hermes-1 (a
monoclonal antibody that recognizes the N-terminal domain of CD44
and inhibits the HA binding) was added to the cells (1 g/well), and
the cells were incubated at 4°C for 20 minutes before the addition of
the NPs. The solution was aspirated, and the cells were washed with
PBS to remove the unbound antibody. Subsequent steps were per-
formed as described in (2).
Influence of the NP-CD44 Interaction in
Gene Transfection
The cells were transfected with p-gal-loaded NPs. The potential uti-
lization of CD44 to aid in transporting pDNA into the cell nuclei was
investigated by blocking the receptor with Hermes-1 and/or with an
excess of HA/HAO (50-fold in relation to the HA content in the
nanostructures), in which were the cells were incubated for 20 min-
utes at 4°C. The antibody and the free polysaccharide were aspirated.
Subsequently, the loaded NPs were added over the cells (0.5 g/well),
and incubated for 5 hours at 37°C. The solutions of the NPs were
FIGURE 1. Gel retardation assay of
the pEGFP-loaded NPs (7% theoreti-
cal loading) consisting on HA:CS of
different molecular masses and in-
creasing amounts of HA. As controls,
NPs composed solely by CS or CSO
were placed on the gel.
TABLE 1. Size and -Potential of pEGFP-Loaded Nanoparticles with 7% Loading
HA:CS
Mass Ratio

















1:2 163  24 25  6 115  13 20  4 198  20 28  5 103  7 23  10
1:1 160  16 18  3 A A 221  37 16  1 173  53 10  6
2:1 191  16 30  8 A A 235  30 16  9 A A
Data are the mean  SD; n  3. A, aggregation.
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aspirated and replaced with fresh culture medium. Two days after
transfection of the cells, the yield of the transfection was quantified.
For the assay of -galactosidase reporter gene expression, PBS was
added to each well for washing, and then removed. Triton-X (2%) in
PBS was added to each well (50 L), and the cell lysates were obtained
after incubation at 80°C for 15 minutes. Fifty microliters of 0.5% FBS
in PBS were added to each well, and finally, 150 L ONPG solution (2
mg/mL in 60 mM Na2HPO4 buffer [pH 8] containing 1 mM MgSO4, 10
mM KCl, and 50 mM -mercaptoethanol) was added. A standard curve
was made using known concentrations of -galactosidase, and the
amount of expressed protein was estimated by a comparison to the
standards. The plate was eventually assayed, and the absorbance of
each well was measured at 405 nm.
Statistical Analysis
The statistical significance was determined by the two-way ANOVA,
and the t-test (SigmaStat Program, ver. 2.0; SPSS, Chicago, IL). Differ-
ences were considered to be significant at P  0.05.
RESULTS AND DISCUSSION
NP Formation and Characterization
We report the preparation of nanosystems containing different
proportions of HA, as well as the influence of the molecular
weight of both polysaccharides, HA and CS, on the in vitro
behavior of the resulting NPs. The NPs were obtained by a very
mild ionotropic gelification technique, initially applied to the
preparation of CS NPs.25 The mechanism of formation of the
nanosystems combines the electrostatic interaction between
both polysaccharides, which are oppositely charged, with the
ability of CS to undergo a liquid–gel transition because of its
ionic interaction with TPP. In addition, both polysaccharides
were expected to interact through hydrogen bonds and other
intermolecular forces.26 On the other hand, pDNA was effi-
ciently entrapped because of the strong interaction between
its phosphate groups with the amino groups of CS, in addition
to hydrophobic and hydrogen bonds between CS and the
nucleotides.21
Based on the hypothesis that the presence of HA in the NPs
is critical for their utility in ocular gene delivery, we have
prepared NPs with HA:CS mass ratios from 1:2 to 2:1. More-
over, for the preparation of these NPs we have used not only
the commercially available polysaccharides (HA 160 kDa and
CS 125 kDa) but also oligomers obtained by partial depolymer-
ization of the originals (HAO 10 kDa and CSO 10–12 kDa). In
contrast, we have studied the influence of the amount of pDNA
in the NPs formation process and observed that NPs could be
obtained with a theoretical loading as high as 7% (7 mg of
plasmid DNA/100 mg of polysaccharides).
As shown in Table 1, the size and -potential of the nano-
carriers were dependent on the composition. In general, the
reduction in CS molecular weight is accompanied by a de-
crease in the size of the NPs. The same observation was made
for NPs composed solely by CS (CS NPs: 223  18 nm; CSO
NPs: 151  10 nm).
It should be noted that there was a slight increase in size
and a decrease in the surface charge due to the function of the
HA content. More specifically, the NPs containing the highest
amount of HA (HA:CS 2:1) underwent an inversion in their
-potential, from positive to negative, thus indicating the dis-
position of the HA on the NP surface. This charge inversion
was not observed in the case of HAO:CS 2:1 NPs, probably
because of the different location of the HAO in the NP struc-
ture.
FIGURE 2. Light microscopy images showing the expression of CD44
receptor (brown) in (A) HCE cells visualized after immunostaining
with anti-human CD44 antibody Hermes-1 and (B) IOBA-NHC cells
visualized after immunostaining with anti-human CD44 antibody
Hermes-1. The negative controls were performed by using the same
protocol but without incubation of the primary CD44 antibody
Hermes-1 in the (C) HCE cells and (D) IOBA-NHC cells. Magnification:
(A, B) 10; (C, D) 20.
FIGURE 3. Cell viability on exposure to increasing doses of 7% pEGFP-
loaded NPs (HA:CS mass ratio 1:2). Comparison of HA:CS, HA:CSO,
HAO:CS, and HAO:CSO NPs. The NPs were incubated for 1 hour with
(A) HCE and (B) IOBA-NHC cells, and an MTS assay was subsequently
performed (mean  SD, n  3). *Significant differences, P  0.05.
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The ability of the polysaccharide NPs to entrap pDNA was
studied by using an agarose gel electrophoresis technique. In
general, the results observed for the NPs showed no migration
of free pDNA in the gel, thus indicating that the pDNA was very
efficiently associated with the NPs (Fig. 1). This result can be
explained by the high affinity of the polysaccharide CS for the
nucleotides.21–23
Analysis of the CD44 Expression in Corneal and
Conjunctival Cells by Immunohistochemistry
As indicated in the introduction, one of the mechanisms
whereby hyaluronan is thought to affect cellular events is via
interaction with cell surface receptors, such as CD44. The
ubiquitous plasma membrane CD44 receptor is known to be
expressed in normal human and conjunctival cells13,14 and to
contribute to hyaluronan internalization.15,16 Thus, given the
expected critical role of the CD44 receptor in the internaliza-
tion of NPs, in the present study, we used immunochemistry to
examine the expression of this receptor in two model cell
lines: HCE and IOBA-NHC. The results of the immunostaining
with anti-human CD44 antibody Hermes-1 indicated that both
HCE and IOBA-NHC cells had a high expression of the CD44
receptor in the study’s experimental conditions (Fig. 2). Con-
sequently, the selected cell lines can be considered to be good
models for studying the internalization and DNA delivery ca-
pacity of HA-CS NPs.
Study of the Cytotoxicity of HA-CS NPs
A very important aspect of the development of new gene
delivery carriers is the analysis of their toxicity on interaction
with the target cells. In this study, we evaluated the cytotox-
icity of HA-CS NPs in the HCE and IOBA-NHC cell lines by
measuring their metabolic activity.
Figure 3 displays the percentage of cell viability as a func-
tion of the amount of NPs per square centimeter of cells. A first
observation is that the cell viability values were dependent on
the cell line. The NP compositions exhibited an obviously
higher cytotoxicity in HCE (Fig. 3A) than in IOBA-NHC (Fig.
3B) cells. This behavior could simply be attributable to the
different nature of the cells. Nevertheless, irrespective of this
difference, the most important conclusion is that the highest
IC50 (observed in the HCE cells) was between 80 and 160
g/cm2—a value that greatly surpasses the particle concentra-
tion necessary for efficient cell transfection (9.7 g/cm2).
An additional observation from Figure 3 is that the toxicity
profiles of the nanosystems are very similar, independent of the
molecular weight of the polysaccharides. Only significant dif-
ferences were noted at the highest doses tested (80 and 160
g/cm2) for the NPs composed by HA:CSO (1:2), which ren-
dered higher values on the levels of cell viability on incubation
in HCE (Fig. 3A).
FIGURE 4. Levels of cell viability of (A) HCE and (B) IOBA-NHC cells,
measured after a 1-hour incubation with 7% pEGFP-loaded NPs, com-
posed of solely CS () or CS in combination with increasing amounts
of HA (HA:CS 1:2, F; HA:CS 1:1. f; and HA:CS 2:1. Œ mean  SD,
n  3). *Significant differences, P  0.05.
FIGURE 5. Evaluation of the transfection efficiency of HA-CS NPs in
HCE cells. Percentage of transfected cells over 10 days after incubation
of NPs composed of variable HA:CS ratios and different HA molecular
weight (A). NPs composed solely of CS, HA:CS 1:2, HA:CS 1:1, HA:CS
2:1, HAO:CS 1:2, HAO:CS 1:1, or HAO:CS 2:1 NPs or of naked pDNA.
(B) NPs composed solely of CSO, HA:CSO 1:2, HAO:CSO 1:2, or
HAO:CSO 1:1 NPs or of naked pDNA (mean  SD, n  3).
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As a second step, with the idea of investigating the influ-
ence of the HA content of the NPs on their cytotoxicity, we
incubated NPs composed solely of CS or CS in combination
with increasing amounts of HA (NPs with a HA:CS mass ratios
of 1:2., 1:1, and 2:1). We found that cellular toxicity depended
on the HA content (Fig. 4).
As the amount of HA present in the NPs increased, a de-
crease in cellular toxicity was observed. In addition, the viabil-
ity of the recovered cells was totally preserved on incubation
of the HA:CS 2:1 NPs, irrespective of the dose. This positive
feature could be explained by the high biocompatibility of the
glycosaminoglycan hyaluronan and its implication in biological
processes, such as the regulation of corneal epithelial regener-
ation, promotion of epithelial migration and wound healing,
through an interaction with its receptor CD44.12
Overall, these findings indicate an adequate safety range for
the application of these particles in ocular gene delivery.
Transfection Efficiency of pDNA-Loaded NPs in
Proliferating Ocular Cell Lines
In the present work, we studied the capacity of the nanosys-
tems to transfect two cell lines derived from the human corneal
and conjunctival epithelia (HCE and IOBA-NHC). For this pur-
pose, we used a green fluorescent protein–encoding plasmid
(pEGFP) as a reporter gene. The GFP expression was observed
for up to 10 days under a fluorescence microscope.
Figure 5 shows the levels of expressed green protein ob-
tained after incubation of the pEGFP-loaded NPs in the HCE
cell model. The results show that the ability of the NPs to
transfect cells was strongly influenced by their composition.
An additional observation is that the level of GFP expression
increased with the amount of HA included in the nanostruc-
tures. This enhancement of the transfection efficiency could be
a result of the presence of HA in the NP composition. First, HA
could be expected to improve the internalization of the NPs as
a result of specific and nonspecific interactions with the cells.
Second, it has been reported that on internalization, HA is
included in nonlysosomal vesicular compartments and rapidly
accumulated in the perinuclear region and cell nuclei.28–30
Hence, trafficking could be speculated for the NPs containing
HA that undertake intracellular pathways that favor the gene
expression.31 Third, HA has been described as a transcription
activator, that is able to enhance the transfection efficiency of
HA-coated PEI complexes.32 Consequently, the same type of
mechanism could apply to the HA-CS NPs.
An additional observation from the data in Figure 5 is that
NPs made of oligomeric HA give lower levels of expression
than those made of polymeric HA. This decrease in gene
transfection efficiency could be related to a different location
of HAO or to a reduced degree of incorporation of HAO into
the NPs. Of interest, an opposite effect of molecular mass was
noted for CS. In particular, the formulations composed by CSO
promoted higher levels of gene expression than those made of
CS. More specifically, the levels of gene expression exhibited
by HA:CSO 1:2 NPs (Fig 5B) were notably higher than those
corresponding to the HA:CS 1:2 NPs (Fig 5A). This result agrees
with those reported by Köping-Höggård et al.,33 who related
the higher early expression with a more rapid release of the
plasmid DNA from the NPs composed by CSO. Consequently,
when taken altogether these results suggest that the most
promising nanocarrier is that composed of CSO and HA.
The results obtained after transfection of the IOBA-NHC
cells with the pEGFP-loaded NPs are shown in Figure 6. Naked
pDNA was placed as a control, and no expression of the
protein was detected. Overall, the obtained results correlate
well with those reported for the HCE cell line, especially with
regard to the factors that affect the efficacy of the nanosystems.
However, a critical difference can be noted in the levels of
gene expression achieved in each case. In fact, the NPs com-
posed of solely CS were not able to transfect IOBA-NHC cells
effectively and rendered undetectable levels of gene expres-
sion. Only those NPs containing important amounts of HA
(HA:CS 1:1 and 2:1) elicited significant transfection levels (Fig.
6A). Undetectable levels of gene expression were also found
for the NPs composed solely by CSO. The formulation contain-
ing CSO and HA or HAO (Fig. 6B) rendered levels of transfec-
tion that were closer to the ones reported for HCE cells.
A possible explanation for the different gene expression
intensity obtained with both ocular cell lines could be related
to their different surface properties, which could affect the
interaction and internalization of the nanosystems. A crucial
distinction between both cell lines relies on the fact that
IOBA-NHC cells express mucins on their surface.34 Mucin may
make it more difficult for the NP to interact with membrane
receptor of the cells, thus affecting their internalization. Nev-
ertheless, more experiments would be necessary to verify this
possibility.
Study of the Cellular Uptake of NPs
In an attempt to elucidate whether the differences reported in
the levels of transfection efficiency of the HCE and IOBA-NHC
cells could be related to the transcellular penetration of the
carriers, we decided to investigate the internalization of fluo-
FIGURE 6. Evaluation of the transfection efficiency of HA-CS NPs in
NHC cells. Percentage of transfected cells over 10 days after incubation
of NPs composed of variable HA:CS ratios and different HA molecular
weight. (A) NPs composed of HA:CS 1:1 and HA:CS 1:2. Undetectable
levels of protein expression were found for CS; HA:CS 1:2; or HAO:CS
1:2, 1:1, and 2:1 NPs or naked pDNA. (B) NPs composed of HA:CSO
1:2, HAO:CSO 1:2, or HAO:CSO 1:1. Undetectable levels of protein
expression were found with CSO NPs and naked pDNA (mean  SD,
n  3).
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rescence-labeled NP by using a confocal microscope. For this
study, we selected the NPs composed of HA:CSO (1:2) given
their optimal transfection results, and also the formulations
consisting of HA:CS (1:2) and HA:CS (2:1). This last formulation
has a negative -potential, probably due to the disposition of
the HA on the NP surface and also gave reasonable high levels
of gene expression in HCE and IOBA-NHC cells.
As noted by the localization of the intense green signal
corresponding to the NPs, the images in Figure 7 indicate that,
irrespective of their composition, the NPs are effectively inter-
nalized by the cells. An additional observation from these
images is that, the ability of the NPs to enter the cells is more
remarkable for HCE cells than for IOBA-NHC cells. These re-
sults, which are in good correlation with the transfection
results, suggest that the internalization process is a limiting
step for the efficiency of these nanocarriers as transfecting
vehicles. Taking into account that a critical difference between
both cell lines is the presence of mucin on the surface of
IOBA-NHC cells,34 we could speculate about the possibility
that the interaction of the nanosystems with the cell is some-
how hampered by this additional barrier. From these results,
we decided to conduct studies to elucidate further the mech-
anism of particle internalization by the cells in the HCE cell
line.
Study of the Mechanism of Internalization of NPs:
the Role of the CD44 Receptor in HCE Cells
CD44 is the primary cell surface receptor for HA internalization
and turnover.15,16 The HA binding to the cell surface is a
complex interplay of multivalent events affected by the size of
the HA ligand, the quantity and density of the cell surface
receptor, and the activation state of CD44.35 Based on this
information, we expected that the presence of HA in the NPs
would facilitate their access to the target cells and hence be
critical to their success as gene carriers. In addition to this
positive feature, it has been reported that the HA-CD44 inter-
action leads to a cellular signaling process,12,36 which could
promote the success of the gene transfection.
Particles with suitable sizes can enter mammalian cells by
several routes (e.g., pinocytosis, phagocytosis, receptor-medi-
ated uptake). In the particular case of NPs, the mechanism of
internalization is thought to be an endocytic pathway.37,38 In
the present work, we decided to evaluate whether HA:CS NPs
could have access to cells through specific interaction with the
transmembrane HA receptor, CD44. With this purpose in
mind, we used fluoresceinamine-labeled NPs composed of HA:
CSO (1:2; highest transfection efficiency) and compared them
with those composed of HA:CS (2:1; higher HA content).
Taking into account that the HA-receptor binding proceeds
at 4°C and 37°C, whereas endocytosis occurs only at 37°C, we
FIGURE 7. Confocal images show-
ing the cellular uptake of (1) HA-fl
solution, (2) HA:CSO mass ratio 1:2,
(3) HA:CS mass ratio 1:2, or (4)
HA:CS mass ratio 2:1 NPs after 1 hour
of incubation with HCE or IOBA-
NHC cells. The images are the pro-
jection of x–y sections. HA was la-
beled with fluoresceinamine (green),
and the cell nuclei stained with pro-
pidium iodide (red). Magnification,
63.
FIGURE 8. Confocal images showing the internalization of (A) HA:
CSO (mass ratio, 1:2), and (B) HA:CS (mass ratio, 2:1) NP in HCE cells.
The NPs were incubated at 37°C (1), 4°C (2), and 4°C after blocking of
the CD44 receptor with the monoclonal antibody Hermes-1 (3). The
images show cross sections in the x–y and x–z axes of the series. HA
was labeled with fluoresceinamine (green), and the cell nuclei were
stained with propidium iodide (red). Magnification, 63.
FIGURE 9. Evaluation of the transfection efficiency of pDNA-loaded
NPs (HA:CSO 1:2) on incubation with HCE cells. The NPs were added
over the cells. The CD44 receptor was blocked with 1 g of the
monoclonal antibody Hermes-1 or with an excess of a HA/HAO mix-
ture (50-fold with respect to the amount of HA forming the nanostruc-
tures). The expressed -galactosidase was quantified by the ONPG
reaction. (mean  SD, n  3). *Significant difference, P  0.05.
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decided to conduct the internalization studies in both condi-
tions. As observed in Figure 8, NPs were extensively internal-
ized at 37°C, thus evidencing an endocytic mechanism of
uptake. However, some cell association was also observed at
4°C, a result that suggests a receptor-mediated uptake. Then,
with the objective of elucidating whether CD44 is responsible
for the receptor-mediated uptake, we blocked the receptor by
the addition of the monoclonal antibody Hermes-1. The results
showed that, as expected, the uptake of the NPs was almost
negligible after the receptor blockage. Consequently, we con-
cluded the internalization of HA:CS NPs may occur by CD44
receptor-mediated endocytosis.
Consequently, these findings suggest that both adsorptive
and CD44 receptor–mediated endocytosis are involved in the
mechanism of internalization of HA:CS NPs by the HCE cells.
Finally, after the observation of the capacity of the NPs to
interact with the CD44 receptor, we thought it important to
evaluate the influence of this interaction in the transfection
efficiency of the p-gal-loaded HA:CSO 1:2 NP. For this pur-
pose, we blocked the CD44 receptor by adding anti-CD44
antibodies, or by excess of HA, before the addition of the
plasmid DNA-loaded NPs. As shown in Figure 9, the levels of
the expressed -galactosidase were strongly diminished when
the CD44 receptor was blocked. Therefore, we can conclude
that the mechanism of transfection is partially governed by the
interactions between the NPs and the HA receptor CD44.
CONCLUSIONS
In this report, we present a new type of NP consisting of HA
and CS, which exhibit very low cytotoxicity, an ability to enter
the corneal epithelial cells by CD44 receptor–mediated endo-
cytic uptake, and the crucial capacity to deliver pDNA into
both the corneal and the conjunctival cells, thus eliciting ef-
fective levels of protein expression. Therefore, these new NPs
can be considered a promising means of ocular gene delivery.
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